ScholarIQanswers from OpenAlex

Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy

PaperCitations, authors & open-access status

Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy have?

ScholarIQcitation count

Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy has 126 citations in the OpenAlex counts ScholarIQ stores.

When was Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy published?

ScholarIQyear

Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy has 2006 year in the ScholarIQ index.

What is the open-access status of Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy?

ScholarIQoa status

Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy has closed oa status in the ScholarIQ index.

What is the DOI of Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy?

ScholarIQdoi

The DOI for Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy is on the source record.

What is the PMID of Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy?

ScholarIQpmid

The PMID for Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy is on the source record.

What is the OpenAlex record for Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy?

ScholarIQopenalex

The OpenAlex for Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial